| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 176,791 | 132,611 |
| Distributions from unconsolidated subsidiaries | 42,815 | 31,092 |
| Depreciation and amortization | 104,098 | 69,656 |
| Provision for expected credit losses | 2,061 | 1,555 |
| Equity in earnings of unconsolidated subsidiaries | 39,122 | 26,130 |
| Loss on extinguishment of debt | 0 | - |
| Gain on sale or disposal of assets | 47 | 43 |
| Stock compensation expense | 12,179 | 7,924 |
| Amortization of debt discount, premium, and issuance costs | 2,353 | 1,569 |
| Deferred income taxes | 10,547 | -7,348 |
| Accounts receivable | 6,487 | 89,631 |
| Other current assets | 7,498 | -562 |
| Other assets | -5,056 | -3,459 |
| Accounts payable | 17,772 | 21,094 |
| Accrued expenses | -38,376 | -39,535 |
| Net cash provided by operating activities | 282,142 | 106,835 |
| Proceeds from sale of assets | - | 39 |
| Business combinations, net of cash acquired | 1,601 | 0 |
| Purchases of property and equipment | 170,125 | 117,023 |
| Proceeds from sales and exchange of assets | 22,132 | - |
| Net cash used in investing activities | -149,594 | -116,984 |
| Borrowings on revolving facilities | 970,000 | 770,000 |
| Payments on revolving facilities | 925,000 | 625,000 |
| Proceeds from term loans, net of issuance costs | 0 | - |
| Payments on term loans | 7,875 | 5,250 |
| Proceeds from 6.875 senior notes, net of issuance costs | 0 | - |
| Borrowings of other debt | 41,522 | 21,353 |
| Principal payments on other debt | 25,965 | 16,691 |
| Dividends paid to common stockholders | 23,684 | 15,945 |
| Repurchases of common stock | 99,535 | 97,565 |
| Decrease in overdrafts | -25,803 | -9,297 |
| Proceeds from issuance of non-controlling interests | 12,964 | 10,906 |
| Distributions to and purchases of non-controlling interests | 48,812 | 29,707 |
| Proceeds from concentra initial public offering | 0 | - |
| Net cash used in financing activities | -132,188 | 2,804 |
| Net increase in cash and cash equivalents | 360 | -7,345 |
| Cash and cash equivalents at beginning of period | 59,694 | - |
| Cash and cash equivalents at end of period | 60,054 | - |
SELECT MEDICAL HOLDINGS CORP (SEM)
SELECT MEDICAL HOLDINGS CORP (SEM)